As COVID-19 becomes a business, vaccine makers confront thorny pricing questions
Bio Pharma Dive
FEBRUARY 9, 2021
Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots?
Sat.Feb 06, 2021 - Fri.Feb 12, 2021
364 
The other COVID-19 health crisis in Oncology
World of DTC Marketing
FEBRUARY 11, 2021
SUMMARY : COVID-19 has caused substantial increases in the number of avoidable cancer deaths due to diagnostic and treatment delays. People who need healthcare are avoiding it because of COVID-related concerns, and in some cases, it costs them their lives. Where are healthcare companies? Recent data has revealed that the increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases, including cancer.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
First look inside BioNTech's Marburg site as it starts production for COVID-19 vaccine
BioPharma Reporter
FEBRUARY 10, 2021
BioNTech announced this morning it has started the production of mRNA at its new facility in Marburg, Germany: which will become one of the largest mRNA manufacturing sites in Europe.
Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program
BioSpace
FEBRUARY 10, 2021
The company’s head of drug development, Samit Hirawat, told analysts in a conference call last week that the decision was about working with the best drugs, particularly in a crowded field like BCMA.
In surprise finding, Roche arthritis drug cuts risk of COVID-19 death in large UK study
Bio Pharma Dive
FEBRUARY 11, 2021
U.K. researchers running the sprawling RECOVERY trial showed that adding Actemra to standard treatment can save lives, a powerfully positive result in a long-running debate about the drug's utility in COVID-19.
Let your agency do what they do best
World of DTC Marketing
FEBRUARY 10, 2021
SUMMARY: There are some excellent digital agencies dedicated to pharma. Greater-Than-One and InTouch Solutions are just a couple. Agencies have experience in leading and developing cutting-edge digital pharma marketing solutions, but they need your help to really be effective. Agencies should never be considered vendors; they are your marketing partners.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Triple Negative Breast Cancer Drug Development Digital Summit
pharmaphorum
FEBRUARY 10, 2021
Improving the Safety, Efficacy & Predictability of Monotherapy & Combinatorial Therapies to Fast-track the Discovery & Development of TNBC Treatments to Reach Patients in Need. This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.
New data on AstraZeneca vaccine add to worries over coronavirus variant from South Africa
Bio Pharma Dive
FEBRUARY 8, 2021
South Africa will use other shots in its immunization campaign after AstraZeneca's offered "minimal protection" against the variant that's spread throughout the country.
Elements of a great pharma website
World of DTC Marketing
FEBRUARY 9, 2021
OPENING: Online health seekers decide whether to stay on your website within the first five seconds of landing on your homepage. They decide if your site addresses their questions after looking at 1.24 pages. Here are what I found in over two years of research with online health seekers. Remember that every health condition has particular needs and wants by their audience, but it’s clear that certain qualities overlap.
How CureVac is creating a ‘broad pipeline’ of both first and second generation COVID-19 vaccines
BioPharma Reporter
FEBRUARY 8, 2021
CureVac aims to bring together expertise from both its own company and other stakeholders to provide âbroader and faster protection against current and future viral threatsâ: through collaborations with the UK Government, Bayer and GSK all announced this month.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Early data back J&J and AC Immune’s Alzheimer’s jab
pharmaphorum
FEBRUARY 11, 2021
Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s disease (AD) hit the mark in a phase 1/2 trial. . ACI-35.030, partnered with Johnson & Johnson, is designed to stimulate the body to generate antibodies against tau protein, one of the factors though to play a role in the development of AD dementia.
A new startup gets Takeda's backing to take complex genetic medicines 'off the shelf'
Bio Pharma Dive
FEBRUARY 11, 2021
Ensoma Therapeutics debuts with a lucrative alliance with the Japanese pharma and an unusual way to deliver genetic medicines into the body.
Navigating the Minefield of Organ Donation During the COVID-19 Pandemic
BioSpace
FEBRUARY 7, 2021
When all is said and done, there will have been many forgotten victims of COVID-19. With the SARS-CoV-2 virus showing up in more and more human organs, will potential recipients be among them?
France ramps up COVID-19 vaccine production
BioPharma Reporter
FEBRUARY 10, 2021
Three COVID-19 vaccine manufacturing sites are set to start production in France in the coming weeks: while the French government is seeking to boost further production with a â300m ($363m) initiative announced on Monday.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Ireland is open: The biologics boom boosting the Irish economy
pharmaphorum
FEBRUARY 12, 2021
The life sciences industry has an important role in the Irish economy, with sectors such as biologics booming across the country. Rory Mullen, head of biopharma at Ireland’s economic development agency IDA Ireland tells pharmaphorum why business is blossoming in the Emerald Isle. With an attractive corporate tax rate and the youngest workforce in the EU, Ireland continues to be a popular destination for life science companies to settle.
AbbVie exploring how CRISPR gene editing can improve cell therapies
Bio Pharma Dive
FEBRUARY 10, 2021
Using technology from Caribou Biosciences, AbbVie hopes to engineer "off-the-shelf" CAR-T cells that can better withstand attacks from the immune system.
South Africa Pauses AstraZeneca Vaccine Rollout Over Small but Dismal Study Results
BioSpace
FEBRUARY 7, 2021
South Africa has delayed the distribution of the AstraZeneca-University of Oxford COVID-19 vaccine after data suggested it “provides minimal protection” against mild disease from the South African variant.
Synairgen’s inhaled COVID-19 treatment included in US trial
Pharma Times
FEBRUARY 10, 2021
Trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID)
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Labour accuses government of cronyism in COVID-19 contracts
pharmaphorum
FEBRUARY 9, 2021
The UK government’s massive spending on the coronavirus pandemic response has been “rife with conflicts of interest”, says the opposition Labour Party, and an independent watchdog should be set up to oversee procurement contracts. That was the message delivered by shadow Cabinet Office minister Rachel Reeves in a speech yesterday which claimed almost £2 billion of the £23.1 billion public sector spend on the pandemic went on contracts that were awarded to “Conservative friends and donors”
A gene therapy pipeline takes shape for a cluster of rare diseases
Bio Pharma Dive
FEBRUARY 12, 2021
Lysosomal storage disorders, diseases of cellular metabolism gone wrong, are the focus of a fast-expanding lineup of experimental genetic medicines, a research boom that recalls biotech's roots.
Avrobio Gene Therapy Shows Early Promise in Fabry, Other Rare Lysosomal Diseases
BioSpace
FEBRUARY 7, 2021
Shares of Avrobio were up nearly 20% in premarket trading after the company posted positive clinical data from its gene therapy trials in three different rare lysomal diseases, Fabry, Gaucher type 1 and cystinosis.
Jazz Pharmaceuticals to acquire GW Pharma for $7.2bn
Pharma Times
FEBRUARY 8, 2021
Jazz will add GW's plant-derived cannabinoid treatment Epidiolex to its roster
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
performance-io strikes multimillion-pound deal with STEM’s Rob Wood
pharmaphorum
FEBRUARY 11, 2021
Rob Wood has acquired a large minority stake in performance-io through a multimillion-pound deal that will see him join the specialist online performance marketing agency’s executive board. A former AstraZeneca director, Wood founded commercial and medical benchmarking firm STEM in 2007 before selling it to UDG Healthcare for £84 million in 2016. Since leaving that company he has invested in a number of disruptive technology-driven pharma service providers. performance-io ’s founder and CEO Matt
Lilly CFO steps down after investigation found 'inappropriate' behavior
Bio Pharma Dive
FEBRUARY 9, 2021
Josh Smiley had engaged in "consensual though inappropriate" personal communications with certain employees, according to Lilly. He's being replaced by Anat Ashkenazi, chief financial officer of Lilly Research Laboratories.
COVID-19 Long-Hauler Therapy Space Beginning to Take Shape
BioSpace
FEBRUARY 8, 2021
While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.
Antibiotic Research UK calls for clear guidance on the use of antibiotics and COVID-19 vaccines
Pharma Times
FEBRUARY 9, 2021
Charity has urged the UK government to provide clarity on whether people receiving antibiotics can receive a COVID-19 vaccination
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs
pharmaphorum
FEBRUARY 12, 2021
Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalosporin franchise. . The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets around the world and had sales of around $140 million last year.
Editas names new CEO in latest executive shakeup
Bio Pharma Dive
FEBRUARY 8, 2021
James Mullen, chair of Editas' board and a former Biogen CEO, will replace Cynthia Collins in a critical year for the gene editing biotech.
Janssen Shows 35% Drop in Mortality with Prostate Cancer Drug
BioSpace
FEBRUARY 8, 2021
A final analysis of the Phase III TITAN study shows that Janssen’s ERLEADA®, when added to androgen deprivation therapy, significantly improved overall survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with placebo.
Say ‘NO’ to bad contracts
Drug Patent Watch
FEBRUARY 11, 2021
Are you tired of having to naviagate complicated contracts to access the information you need? Let DrugPatentWatch free you from weeks of negotiating complex contracts and let you focus on…. The post Say ‘NO’ to bad contracts appeared first on DrugPatentWatch - Make Better Decisions.
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Let's personalize your content